Evvy Secures $40M Series B Funding to Expand Women's Health Research Using Vaginal Microbiome Data
Women’s health company Evvy has raised a $40 million Series B funding round led by Catalio Capital Management. The startup, founded in 2021 and known for its at-home CLIA- and CLEP-certified mNGS test to analyze vaginal microbiomes, aims to expand research using data from over 100,000 patients across the U.S. Evvy’s platform enables clinicians to review patient results and provide personalized care. The company has published 15 peer-reviewed studies, identified novel bacterial vaginosis subtypes, and discovered hundreds of new vaginal microbiome genomes. Its broader goal is to build a comprehensive dataset linking microbiomes with health outcomes, aiming to improve precision medicine for women. Evvy also launched an AI assistant called EvvyAI in May 2024 to provide real-time guidance based on its data. The company plans to expand into fertility research and develop new diagnostic tools such as an at-home Pap smear alternative.
